New agreement integrates Dario's
cardiometabolic suite into Amwell's market leading digital care
delivery enablement platform covering over 90 million lives
NEW
YORK, March 22, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital therapeutics (DTx) market, announced today a
strategic partnership with Amwell® (NYSE: AMWL), a
leader in digital healthcare enablement, to deliver its
cardiometabolic solution to Amwell customers. Dario's solution will
be available through Amwell beginning in the second half of
2023.
The agreement is part of Dario's strategy to partner with market
leading strategic partners to accelerate adoption of Dario's
solutions by making the Dario solution available to existing Amwell
customers. The integration into Amwell will support a more
continuous and connected member journey by providing Dario's
cardiometabolic solution as part of Amwell's comprehensive
portfolio of care solutions and network of affiliated clinicians.
Members living with cardiometabolic health concerns such as
diabetes, high blood pressure and weight management challenges will
have access to Dario's proven and highly personalized digital
solution to help better manage their condition and improve outcomes
between visits with clinicians practicing on the Amwell platform.
Members can access Dario's solutions directly through Amwell's
digital care delivery enablement platform to support ease of
engagement.
"Amwell is a recognized leader in digital care delivery
enablement covering 90 million lives through its substantial
footprint of clients. We are proud to partner with them to take the
Dario cardiometabolic suite to our target markets," said
Rick Anderson, President of Dario.
"Leveraging the power of our combined offering to enhance care and
support for members, benefits everyone. This partnership fits the
clear market demand for more condition solutions from less vendors
and lowers the cost of delivering high value innovative digital
health for buyers."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital
therapeutics (DTx) company, revolutionizing how people with chronic
conditions manage their health through a user-centric,
multi-chronic condition platform. Our platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Our user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about DarioHealth and its digital
health solutions, or for more information, visit
http://dariohealth.com.
About Amwell
Amwell is a leading digital care delivery enablement platform in
the United States and globally,
connecting and enabling providers, insurers, patients, and
innovators to deliver greater access to more affordable, higher
quality care. Amwell believes that digital care delivery will
transform healthcare. The Company offers a single, comprehensive
platform to support all digital health needs from urgent to acute
and post-acute care, as well as chronic care management and healthy
living. With over a decade of experience, Amwell powers the digital
care of more than 55 health plans, which collectively represent
more than 90 million covered lives, and many of the nation's
largest health systems, representing over 2,000 hospitals, have
access to Amwell solutions. For more information, please
visit https://business.amwell.com/.
©2023 American Well Corporation. All rights reserved.
Amwell®, SilverCloud®, Conversa®, ConvergeTM, CarepointTM and the
Amwell Logo are registered trademarks or trademarks of American
Well Corporation. All other trademarks are the property of their
respective owners.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the expected launch of its solution through Amwell, and that the
partnership fits the market demand for more condition solutions
from less vendors and lowers the cost of delivering high value
innovative digital health for buyers. Without limiting the
generality of the foregoing, words such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo:
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/dario-announces-strategic-partnership-with-amwell-to-expand-access-to-its-cardiometabolic-digital-therapeutic-solution-301778487.html
SOURCE DarioHealth Corp.